Lifestyle Intervention Requirements for Novel Antiobesity Medications-Necessary Adjunct or Harmful Gatekeeper?

Ilya Golovaty; Scott Hagan

doi:10.1001/jamainternmed.2024.6450

Lifestyle Intervention Requirements for Novel Antiobesity Medications-Necessary Adjunct or Harmful Gatekeeper?

JAMA Intern Med. 2024 Nov 25. doi: 10.1001/jamainternmed.2024.6450. Online ahead of print.

Authors

Ilya Golovaty^{1

2}, Scott Hagan^{1

2}

Affiliations

¹ VA Puget Sound Health Care System, Seattle, Washington.
² Division of General Internal Medicine, University of Washington, Seattle.

PMID: 39585703
DOI: 10.1001/jamainternmed.2024.6450

No abstract available

Plain language summary

This Viewpoint discusses how prerequisite comprehensive lifestyle interventions for novel antiobesity medications may disproportionately impact patients at highest risk of obesity-related complications and perpetuate disparities in care.